




**Supplementary Fig. 1. Funnel plot for efficacy of bisphosphonates drugs in reducing the risk of subsequent fractures.** (A) Ibandronate. (B) Risedronate. (C) Alendronate. (D) Minodronate. (E) Pamidronate. (F) Etidronate. (G) Zoledronate.




**Supplementary Fig. 2. Funnel plot for the efficacy of non-bisphosphonates drugs in reducing the risk of subsequent fractures.** (A) Denosumab. (B) Teriparatide. (C) Bazedoxifene. (D) Estrogen. (E) Calcitonin. (F) Parathyroid hormone.




**Supplementary Fig. 3. Funnel plot for efficacy of bisphosphonates drugs in changing the bone mineral density.** (A) Pamidronate. (B) Ibandronate. (C) Etidronate. (D) Minodronate. (E) Risedronate. (F) Alendronate. (G) Zoledronate.



**Supplementary Fig. 4. Funnel plot for efficacy of non-bisphosphonates drugs in changing the bone mineral density.** (A) Denosumab. (B) Teriparatide. (C) Bazedoxifene. (D) Estrogen. (E) Calcitonin. (F) Parathyroid hormone.



**Supplementary Fig. 5. Funnel plot for adverse events associated with bisphosphonates drugs.** (A) Ibandronate. (B) Risedronate. (C) Alendronate. (D) Minodronate. (E) Pamidronate. (F) Etidronate. (G) Zoledronate.



**Supplementary Fig. 6. Funnel plot for adverse events associated with non-bisphosphonates drugs.** (A) Denosumab. (B) Teriparatide. (C) Bazedoxifene. (D) Estrogen. (E) Calcitonin. (F) Parathyroid hormone.